title: Cyclosporin A potentiates the dexamethasone-induced mouse mammary tumor virus-chloramphenicol acetyltransferase activity in LMCAT cells: a possible role for different heat shock protein-binding immunophilins in glucocorticosteroid receptor-mediated gene expression.
abstract: As previously observed for FK506, we report here that cyclosporin A (CsA) treatment of mouse fibroblast cells stably transfected with the mouse mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT) reporter plasmid (LMCAT cells) results in potentiation of dexamethasone (Dex)-induced CAT gene expression. Potentiation by CsA is observed in cells treated with 10-100 nM Dex but not in cells treated with 1 microM Dex, a concentration of hormone which results in maximum CAT activity. At 10 nM Dex, 1-5 microM CsA provokes an approximately 50-fold increase in CAT gene transcription, compared with transcription induced by Dex alone. No induction of CAT gene expression is observed in cells treated with CsA or FK506 in the absence of Dex. The antisteroid RU 486 abolishes effects obtained in the presence of Dex. Using a series of CsA, as well as FK506, analogs, including some devoid of calcineurin phosphatase inhibition activity, we conclude that the potentiation effects of these drugs on Dex-induced CAT gene expression in LMCAT cells do not occur through a calcineurin-mediated pathway. Western-blotting experiments following immunoprecipitation of glucocorticosteroid receptor (GR) complexes resulted in coprecipitation of GR, heat shock protein hsp90 and two immunophilins: the FK506-binding protein FKBP59 and the CsA-binding protein cyclophilin 40 (CYP40). Two separate immunophilin-hsp90 complexes are present in LMCAT cells: one containing CYP40-hsp90, the other FKBP59-hsp90. Thus, both FKBP59 and CYP40 can be classified as hsp-binding immunophilins, and their possible involvement as targets of immunosuppressants potentiating the GR-mediated transcriptional activity is discussed.
authors.affiliation: Lab. Hormones, Le Kremlin-Bicêtre, France.
authors.forename: J M
authors.initials: JM
authors.lastname: Renoir
authors.forename: C
authors.initials: C
authors.lastname: Mercier-Bodard
authors.forename: K
authors.initials: K
authors.lastname: Hoffmann
authors.forename: S
authors.initials: S
authors.lastname: Le Bihan
authors.forename: Y M
authors.initials: YM
authors.lastname: Ning
authors.forename: E R
authors.initials: ER
authors.lastname: Sanchez
authors.forename: R E
authors.initials: RE
authors.lastname: Handschumacher
authors.forename: E E
authors.initials: EE
authors.lastname: Baulieu
mesh_terms: D000818:Animals; D015500:Chloramphenicol O-Acetyltransferase / Q000096:biosynthesis*; D016572:Cyclosporine / Q000494:pharmacology*; D003600:Cytosol / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology*; D004357:Drug Synergism; D015870:Gene Expression / Q000187:drug effects*; D007739:L Cells; D008324:Mammary Tumor Virus, Mouse / Q000235:genetics*; D051379:Mice; D011965:Receptors, Glucocorticoid / Q000378:metabolism*; D011994:Recombinant Proteins / Q000096:biosynthesis; D016559:Tacrolimus / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects; D014162:Transfection; D014222:Triamcinolone Acetonide / Q000378:metabolism
chemical_list: D011965:Receptors, Glucocorticoid; D011994:Recombinant Proteins; D003907:Dexamethasone; D016572:Cyclosporine; D015500:Chloramphenicol O-Acetyltransferase; D014222:Triamcinolone Acetonide; D016559:Tacrolimus